SOLO study: A single-pill combination strategy in general practice to optimize blood pressure control in a multi-ethnic community

The SOLO study demonstrates that promoting single-pill combination therapy through a targeted care improvement project in a disadvantaged, multi-ethnic primary care setting significantly increased treatment initiation and improved blood pressure control compared to usual care.

The Gist

Imagine your blood pressure is like the water pressure in your home's plumbing. If the pressure gets too high for too long, it can burst pipes (causing heart attacks or strokes) and damage the whole house.

For a long time, doctors have known that to fix high pressure, you often need to turn on more than one "faucet" (medication) at once. However, many patients struggle because taking three or four different pills every day is confusing, easy to forget, and feels like a chore. This is called "pill burden."

To solve this, doctors created Single-Pill Combinations (SPCs). Think of this as a "super-pill" that combines all the necessary medicines into one tiny tablet. It's like swapping a messy toolbox with three separate wrenches for one multi-tool that does everything at once.

The Problem

Even though doctors know these "super-pills" work better and are easier to take, many general practitioners (GPs) were hesitant to use them. They were worried about side effects or just stuck in old habits of adding one pill at a time. This was especially true in neighborhoods with lower incomes and diverse populations, where managing complex health routines is already tough.

The Experiment: The "SOLO" Project

The researchers in Amsterdam decided to run a real-world experiment called the SOLO project. They wanted to see what would happen if they actively encouraged doctors in a specific neighborhood to start using these "super-pills" right away.

They divided nine local clinics into two groups:

1. The "Coach" Group (Intervention): These doctors were given a clear playbook and a "cheat sheet" on exactly how to prescribe the single-pill combinations. They were coached to switch patients to the "super-pills" immediately.
2. The "Do-Your-Thing" Group (Usual Care): These doctors were just told, "Hey, these pills exist," but they weren't given a specific plan or pressure to change their habits.

What Happened?

The results were like turning a dial on a radio to find a clearer signal:

• More People Switched: In the "Coach" group, doctors started using the "super-pills" for about 25% of their patients. In the "Do-Your-Thing" group, they only did so for about 10%. The coaching worked!
• Pressure Dropped: Because more people were taking the easier-to-manage "super-pills," their blood pressure dropped significantly more in the "Coach" group.
  • The Analogy: Imagine two groups of people trying to lower the water pressure in their houses. The group using the "multi-tool" (SPC) lowered the pressure by 16 points, while the group sticking to the old "separate wrenches" only lowered it by 10 points.
• More People Hit the Goal: Nearly 57% of the "Coach" group reached a safe blood pressure level, compared to only 48% of the other group.

Why Does This Matter?

You might think, "A drop of 5 or 6 points isn't a huge deal for one person." But imagine that happening to thousands of people.

• The Domino Effect: In the world of heart health, even a tiny drop in blood pressure across a whole community is like removing a heavy weight from a bridge. It significantly lowers the risk of the bridge collapsing (heart attacks and strokes) for everyone.
• Fairness: This study happened in a neighborhood where people often struggle with health due to poverty and language barriers. Making treatment simpler (one pill instead of three) helps level the playing field. It removes a barrier that was keeping people from getting healthy.

The Bottom Line

The study shows that when you give doctors a simple, clear plan to use "super-pills" (Single-Pill Combinations), they actually do it. And when they do, patients get better results with less hassle.

It's a reminder that sometimes, the best medical breakthrough isn't a new, expensive drug, but simply making the existing treatment easier to swallow. By simplifying the routine, we can protect more hearts and keep more communities healthy.

Technical Summary

1. Problem Statement

Hypertension remains a critical, modifiable risk factor for cardiovascular disease (CVD), yet blood pressure (BP) control rates remain suboptimal, particularly in socially disadvantaged and multi-ethnic communities. In the Netherlands, only 21% of treated patients achieve adequate BP control, with lower success rates in disadvantaged areas.

• Therapeutic Inertia & Adherence: A primary barrier to control is therapeutic inertia (failure to intensify treatment) and poor medication adherence due to complex regimens (multiple pills).
• Guideline vs. Reality: While major guidelines (ESC/ESH and Dutch primary care guidelines) recommend initiating treatment with Single-Pill Combinations (SPCs) to simplify regimens and improve adherence, real-world uptake in primary care is limited. Physicians often hesitate due to concerns about aggressive initiation and side effects.
• Study Gap: There is a need for real-world evidence demonstrating whether targeted implementation strategies to promote SPC initiation can effectively improve BP control in routine primary care settings, specifically within high-burden, diverse populations.

2. Methodology

Study Design:

• Type: Quasi-experimental, parallel-cluster study.
• Setting: Gezondheidscentrum Holendrecht, a healthcare facility in Amsterdam Zuidoost (a socially disadvantaged, multi-ethnic community in the Netherlands).
• Duration: November 1, 2023 – October 31, 2025 (2 years).
• Clusters: Nine GP clinics within the facility were allocated based on their fixed order of affiliation:
  • Intervention Cluster (IC): 5 clinics.
  • Usual Care Cluster (UC): 4 clinics.

Intervention Protocol:

• IC: GPs received case-specific guidance to initiate SPC therapy for patients with primary hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg).
  • SPC Formulary: Developed in co-creation with local pharmacists, consisting of three intensity levels (Low, Medium, High) based on combinations of Amlodipine, Valsartan, and Hydrochlorothiazide.
  • Support: Training via team meetings, individual sessions, and collaboration with community pharmacies to ensure medication availability and switching.
• UC: GPs were informed about SPC options but received no specific recommendations or protocol support; they continued standard care.

Study Population:

• Inclusion: Adults (≥18 years) with documented hypertension (ICPC codes K85, K86, K87) between Nov 2023 and Oct 2025.
• Exclusion: Major CVD at baseline, no follow-up BP measurements (<7 days), or care managed by hospital specialists.
• Final Sample: 438–440 patients (199 in IC, 239 in UC).

Data & Analysis:

• Outcomes: SPC uptake, changes in Systolic (SBP) and Diastolic (DBP) BP, target BP achievement, and cardiovascular events (MI, stroke, heart failure, death).
• Statistical Methods: Intention-to-treat (ITT) linear regression (adjusted for age/sex) for BP changes; Cox proportional hazard models for cardiovascular events; As-treated analysis for SPC users.

3. Key Contributions

• Real-World Implementation: Unlike randomized controlled trials (RCTs), this study evaluates a pragmatic care improvement project embedded in routine primary care, offering high ecological validity.
• Targeted Strategy: Demonstrates that a localized, multi-disciplinary approach (GPs + Pharmacists) with a specific protocol can overcome therapeutic inertia in a disadvantaged, multi-ethnic community.
• Equity Focus: Addresses the specific challenge of hypertension management in populations with low socioeconomic status, where complex regimens often lead to poor adherence.

4. Key Results

SPC Uptake:

• Intervention Cluster: SPC initiation increased significantly from 13.1% at baseline to 25.1% at follow-up.
• Usual Care Cluster: SPC use remained stable at 9.6%.
• Difference: Statistically significant increase in the IC compared to UC ($p < 0.001$).

Blood Pressure Control:

• Mean Reductions (ITT):
  • IC: SBP decreased by -15.7 mmHg; DBP by -6.9 mmHg.
  • UC: SBP decreased by -10.4 mmHg; DBP by -4.6 mmHg.
  • Net Difference: The IC achieved significantly greater reductions (Delta SBP: -5.3 mmHg; Delta DBP: -2.3 mmHg).
• Target Achievement:
  • IC: 57.3% achieved target BP.
  • UC: 48.1% achieved target BP.
  • Odds Ratio: Patients in the IC were 1.4 times more likely to reach target BP (95% CI: 1.0–2.1).

As-Treated Analysis (New SPC Users):

• Patients who newly started SPC therapy showed substantial BP reductions: SBP -22.4 mmHg and DBP -10.5 mmHg.
• New SPC users were 1.9 times more likely to achieve target BP compared to non-SPC users.

Safety & Cardiovascular Events:

• Events: 6 major cardiovascular events occurred (4 strokes, 2 MIs); 0 deaths.
• Association: No significant association was found between cluster allocation/SPC initiation and the occurrence of major cardiovascular events (likely due to the short follow-up period and low event count).
• Adverse Events: No increase in adverse events or hypotension was reported.

5. Significance and Conclusion

• Clinical Impact: The study confirms that promoting SPC therapy in primary care leads to superior blood pressure control compared to usual care. Even modest population-level reductions in SBP (e.g., 5 mmHg) are associated with a ~10% reduction in CVD risk.
• Health Equity: The findings are particularly significant for disadvantaged, multi-ethnic communities where hypertension burden is high and control rates are low. SPCs simplify treatment, potentially improving adherence in populations with lower health literacy.
• Implementation Science: The success of the SOLO project suggests that structured, local implementation strategies (combining GP training, pharmacist collaboration, and clear protocols) are effective in translating guidelines into practice.
• Limitations: The study acknowledges limitations including non-randomized allocation (risk of residual confounding), a relatively short follow-up period (limiting CVD event detection), and limited generalizability outside the specific Amsterdam Zuidoost context.

Conclusion: The SOLO care improvement project successfully demonstrated that targeted promotion of Single-Pill Combination therapy in a disadvantaged, multi-ethnic primary care setting significantly increases SPC uptake and improves blood pressure control, supporting its adoption as a pragmatic strategy to address hypertension management gaps.